Fig. 1 · Structure

Documents & Downloads

Sildenafil citrate

Cat. No. A10841 CAS 171599-83-0

PDE5 inhibitor

Sildenafil citrate is a potent phosphodiesterase type 5 (PDE5) inhibitor with IC50 of 5.22 nM.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
PDE5  

Sildenafil citrate Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Sildenafil citrate from 3 published references. In vitro models include CD4+ or CD8+ T cells. In vivo models include P9 C57Bl/6 mouse.

Sildenafil citrate In Vitro Studies

In transfected HEK293-EBNA cells, Sildenafil dose dependently reduced the PDE6D/K-RasG12V-BRET signal, consistent with disruption of the complex, with EC50 = 11.4 μM. In purified ConA-stimulated CD4+ and CD8+ T cells, Sildenafil had no effect on proliferation compared with cultures without Sildenafil. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

BRET signal response in transfected cells

Cell-based study · HEK293-EBNA cells; n ≥ 3 [1]

Transfected HEK293-EBNA cells were treated with Sildenafil for 24 h, with DMSO as the vehicle control. Sildenafil dose dependently reduced the PDE6D/K-RasG12V-BRET signal, consistent with disruption of the complex, with EC50 = 11.4 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PDE6D/K-RasG12V-BRETPDE6D/K-RasG12V-BRET EC50 = 11.4 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
between 320 and 0.018 μM
Exposure duration
Twenty-four hours after transfection, cells were treated for another 24 h
Vehicle
DMSO 0.1% v/v
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Sildenafil

The paper names Sildenafil without stating the salt or form; not verified as the citrate form supplied as A10841. No dose conversion or lot validation.

Results > PDE6D Inhibitor Deltaflexin3 and Sildenafil Combine To Inhibit K-Ras Activity (S49); Materials and Methods > Bioluminescence Resonance Energy Transfer (BRET) Assay (S135, S140, S142); Materials and Methods > Synergy Analysis of Drug Combinations (S159); Figure 5 legend (S228)

PDE6D/K-RasG12V-BRET: PDE6D/K-RasG12V-BRET; comparator: DMSO 0.1% v/v as vehicle control — Results > PDE6D Inhibitor Deltaflexin3 and Sildenafil Combine To Inhibit K-Ras Activity (S49)

Proliferation of ConA-stimulated purified T cells

Cell-based study · CD4+ or CD8+ T cells [2]

Purified CD4+ and CD8+ T cells stimulated with ConA were cultured with or without 50 μg/ml Sildenafil for 3 d. Sildenafil had no effect on proliferation measured by thymidine incorporation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
T cell proliferation was determined by [3H]thymidine incorporationReported result it had no effect on the proliferation of purified CD4+ and CD8+ T cells stimulated with either ConA[2]

Literature-Reported Treatment Conditions

Treatment concentration
50 μg/ml
Exposure duration
3 d
Method
added to the cell cultures
Co-treatment
Other interventions in this design: ConA. Compound effect isolated by the comparison: with or without 50 μg/ml sildenafil.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Sildenafil

The paper names Sildenafil without stating the salt or form; not verified as the citrate form supplied as A10841. No dose conversion or lot validation.

RESULTS > In vitro sildenafil down-regulates the myeloid suppressor cell suppressive marker IL-4Rα (S66); MATERIALS AND METHODS > Drugs and cytokines. (S127); Figure 5. legend (S230, S232)

T cell proliferation was determined by [3H]thymidine incorporation: T cell proliferation was determined by [3H]thymidine incorporation; comparator: without 50 μg/ml sildenafil — RESULTS > In vitro sildenafil down-regulates the myeloid suppressor cell suppressive marker IL-4Rα (S66); Figure 5. legend (S232)

Sildenafil citrate In Vivo Studies

P9 C57Bl/6 mice received Sildenafil citrate at 10 mg/kg intraperitoneally after pMCAo. Intracellular cGMP concentrations significantly increased compared with PBS-treated animals, reaching 1.91 ± 0.38 pmol/mL and 1.87 ± 0.31 pmol/mL at 1 and 3 h after administration, respectively. [3]

Intracellular cGMP response after pMCAo

Animal study · P9 C57Bl/6 mouse [3]

P9 C57Bl/6 mice received a single intraperitoneal dose of Sildenafil citrate at 10 mg/kg after pMCAo. Intracellular cGMP significantly increased to 1.91 ± 0.38 pmol/mL and 1.87 ± 0.31 pmol/mL at 1 and 3 h after administration, respectively, compared with PBS-treated animals.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
concentration of intracellular cGMPReported result significantly increased the concentration of intracellular cGMP to 1.91 ± 0.38 pmol/mL and 1.87 ± 0.31 pmol/mL at 1 and 3 h after administration, respectively, as compared to PBS-treated animals (0.08 ± 0.02 pmol/mL, p < 0.001)[3]

Conditions shared by the study groups

Route
intraperitoneally (i.p.)
Treatment course
a single dose; 5 min after pMCAo; 1 and 3 h after administration
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Sildenafil citrate 10 mg/kgPBS-treated animalssignificantly increased the concentration of intracellular cGMP to 1.91 ± 0.38 pmol/mL and 1.87 ± 0.31 pmol/mL at 1 and 3 h after administration, respectively, as compared to PBS-treated animals (0.08 ± 0.02 pmol/mL, p < 0.001)[3]
Sildenafil citrate 10 mg/kg
Model: P9 C57Bl/6 mouse
Reported limits: Not stated in the sentences used: vehicle. Removed after verification: value.
Methods and source locations

Compound reported in the paper: Sildenafil citrate; Compound label in the paper: Sildenafil

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Ischemia (S2); Methods > Drug treatment (S5); Results > Setup of the animal model and effect of sildenafil on CBF and lesion size (S52)

concentration of intracellular cGMP: concentration of intracellular cGMP; comparator: PBS-treated animals — Results > Setup of the animal model and effect of sildenafil on CBF and lesion size (S52)

Sildenafil citrate 10 mg/kg · Methods > Drug treatment (S5); Results > Setup of the animal model and effect of sildenafil on CBF and lesion size (S52)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 171599-83-0
Applications PDE5 inhibitor
Formula C28H38N6O11S
Molecular Weight 666.7
Synonyms UK-92480 citrate
SMILES
O=C1C(N(C)N=C2CCC)=C2N=C(C3=CC(S(=O)(N4CCN(C)CC4)=O)=CC=C3OCC)N1.O=C(CC(C(O)=O)(O)CC(O)=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 20 mg/mL (29.99 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
30% PEG400+0.5% Tween80+5% propylene glycol

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Sildenafil citrate Research References

  1. [1] Kaya P, Schaffner-Reckinger E, Manoharan GB, et al. An Improved PDE6D Inhibitor Combines with Sildenafil To Inhibit KRAS Mutant Cancer Cell Growth. J Med Chem (2024). PMID: 38758695 DOI: 10.1021/acs.jmedchem.3c02129 Source material
  2. [2] Serafini P, Meckel K, Kelso M, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med (2006). PMID: 17101732 DOI: 10.1084/jem.20061104 Source material
  3. [3] Moretti R, Leger PL, Besson VC, et al. Sildenafil, a cyclic GMP phosphodiesterase inhibitor, induces microglial modulation after focal ischemia in the neonatal mouse brain. J Neuroinflammation (2016). PMID: 27126393 DOI: 10.1186/s12974-016-0560-4 Source material

Added to your cart

View Cart Checkout
Loading...